Quantcast
Last updated on April 18, 2014 at 10:59 EDT

Latest Steatohepatitis Stories

2013-04-29 08:27:39

- Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data Presented at the International Liver Congress 2013 - NORCROSS, Ga., April 29, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today released data that was presented on April 27, 2013 at the International Liver Congress in Amsterdam, The Netherlands. The data were generated by the laboratory of Dr. Scott...

2013-04-28 23:00:55

Oregon State University researchers say omega-3 fatty acid DHA, such as found in Omega XL, has a powerful effect in preventing liver inflammation and fibrosis. Hollywood, FL (PRWEB) April 28, 2013 One of the first studies to directly compare the effects of omega-3 fatty acids DHA and EPA on liver disease was recently published online in the Journal of Nutrition. The study, supported by the USDA National Institute of Food and Agriculture, as well as the National Institutes of Health,...

2013-04-25 10:32:52

Scientists at the Arkansas Children's Nutrition Center, a U.S. Department of Agriculture Agricultural Research Service Human Nutrition Research Center at the University of Arkansas for Medical Sciences, led by Dr. Martin Ronis have determined that dietary substitution of saturated fats enriched in medium chain triglycerides (MCT) for polyunsaturated fat prevents the development of nonalcoholic fatty liver disease (NAFLD). NAFLD occurs in patients with obesity and type II diabetes and is being...

Vitamin E Could Be Used As A Potential Weapon Against Obesity
2013-04-24 05:47:50

redOrbit Staff & Wire Reports - Your Universe Online Vitamin E could be a new weapon in the fight against obesity-related liver disease known as nonalcoholic steatohepatitis (NASH), according to new research conducted by researchers from the Case Western Reserve University School of Medicine, the Cleveland Clinic Foundation and Cornell University. “The implications of our findings could have a direct impact on the lives of the approximately 63 million Americans who are at...

2013-04-11 10:44:56

New research reveals that advanced fibrosis is a significant predictor of mortality in patients with nonalcoholic fatty liver disease (NAFLD), largely brought about by cardiovascular causes. NAFLD alone was not associated with increased mortality according to findings published in the April issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. With super-sized portions, sugary soft drinks and physical inactivity, obesity is on the rise and showing no...

2013-04-09 12:29:04

NORCROSS, Ga., April 9, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced details today on its first-in-man Phase 1 clinical trial that will support a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH, or fatty liver disease) with advanced fibrosis. The Phase 1 Clinical Trial is entitled, "A Multi-Center, Partially Blinded, Maximum Tolerated...

2013-03-05 08:30:26

NORCROSS, Ga., March 5, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that following review of its Investigational New Drug (IND) application, the US Food and Drug Administration (FDA) notified the company that it may proceed with a Phase 1 clinical trial. The first-in-man Phase 1 clinical trial will support a proposed indication of GR-MD-02 for treatment of...

2012-11-10 08:21:34

BOSTON, Nov. 10, 2012 /PRNewswire/ -- Researchers at the University of Missouri determined that cirrhosis was not present in more than one-third of patients who had nonalcoholic fatty liver disease (NAFLD) that led to hepatocellular carcinoma (HCC). The records of 17,785 Medicare patients who had HCC were studied, and it was determined that 16 percent of those patients had NAFLD and no other way of developing cancer. About 64 percent of those patients had nonalcoholic...

2012-07-04 22:46:49

Scientists at Texas Biomed have developed the laboratory opossum as a new animal model to study the most common liver disease in the nation — afflicting up to 15 million Americans — and for which there is no cure. The condition, nonalcoholic steatohepatitis (NASH), resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature of NASH is accumulation of fat in the liver, along with inflammation and functional damage. Most people with...

2012-06-08 09:20:09

A new study from the Virginia Commonwealth University School of Medicine has identified molecular changes responsible for abnormal cholesterol production and metabolism in the livers of patients with a common liver condition, and these changes may explain the severity of a patient's liver disease and risks to their heart health. It is estimated that a third of Americans have a fatty liver. Nonalcoholic fatty liver disease is a very common liver condition. Nonalcoholic steatohepatitis, or...